Media Category: Treatments

20th October 2022, ParadigMS Master Class ParadigMS Foundation organised the first Master Class, focused on MS prognostication in practice: today and future perspectives that took place on Thursday 20th October 2022 in Brussels, Belgium. Here you can review the full keynote on High efficacy treatments in MS. BIOGRAPHY PATRICK VERMERSCH  Patrick Vermersch studied medicine at Lille University Hospital (France), where he graduated in Neurology. Between 1990 and 1994 he pursued his training in basic research fields, mainly in cellular biology, obtaining a PhD addressing biochemical...

09th September 2022, ParadigMS Egypt Symposium ParadigMS Foundation organised, in collaboration with the Egyptian MS Society, a two-day symposium that took place from Thursday 8th September 2022 through Friday 9th September 2022 in Cairo, Egypt. Here you can review the full keynote on Status of New Trials in SPMS PPMS. BIOGRAPHY NIKOLAOS GRIGORIADIS Nikolaos Grigoriadis graduated from the Faculty of Medicine of the Aristotle University of Thessaloniki. He did his PhD thesis and residency in Neurology in the same institution. He has been specialized in clinical and experimental Neuroimmunology...

09th September 2022, ParadigMS Egypt Symposium ParadigMS Foundation organised, in collaboration with the Egyptian MS Society, a two-day symposium that took place from Thursday 8th September 2022 through Friday 9th September 2022 in Cairo, Egypt. Here you can review the full keynote on Update on newest treatment: How to select MS Patients High treatments RWE efficacy. BIOGRAPHY CELIA OREJA-GUEVARA Vice Chair of Neurology and Head of Multiple Sclerosis Center at University Hospital San Carlos, Madrid Professor Celia Oreja-Guevara is Vice Chair of Neurology and Head of Multiple Sclerosis...

9th December 2021, Pre-MENACTRIMS symposium, as a warm-up for the Sixth MENACTRIMS Congress, ParadigMS Foundation organised this enriching Pre-MENACTRIMS Symposium. Here you can review the full keynote on how to mitigate risks in MS. ABSTRACT No two MS patients are the same, and yet only a limited number of disease-modifying therapies are available for MS neurologists to treat their patients. This session guides you in how to manage and mitigate risks associated with treating MS patients. You will take away a set of key messages stemming both from Professor Pugliatti’s own experience...